Neuropeptide Y (NPY) and α-melanocyte-stimulating hormone (α-MSH), two neuropeptides that are synthesized in neurons of the arcuate nucleus of the hypothalamus, exert opposite actions on food intake and body weight. NPY is orexigenic and decreases energy expenditure whereas α-MSH reduces food consumption and stimulates catabolism. α-MSH is an endogenous ligand for the central melanocortin receptors, MC3-R and MC4-R. In order to determine whether α-MSH may act directly on NPY neurons in the arcuate nucleus, we have investigated the possible occurrence of MC3-R and MC4-R mRNA in NPY-expressing cell bodies in the rat hypothalamus. Double-labeling in situ hybridization histochemistry using 35S-labeled (MC3-R or MC4-R) and digoxigenin-labeled (NPY) riboprobes revealed that 38 ± 1% of the NPY mRNA-positive perikarya expressed MC3-R mRNA while only 9 ± 2% of the NPY-producing neurons contained MC4-R mRNA. The proportions of NPY neurons that express MC3-R mRNA or MC4-R mRNA were not significatively different in the anterior and posterior aspects of the arcuate nucleus. The present study shows that a large proportion of NPY neurons in the rat hypothalamus express MC3-R mRNA while a much lower number of NPY neurons express MC4-R mRNA, suggesting that melanocortins may directly modulate the activity of the hypothalamic NPY system, mainly through activation of MC3-R. These data provide additional evidence for the complex interactions between the stimulatory (NPY) and inhibitory (α-MSH) pathways controlling feeding behavior and energy homeostasis.

Keywords:
Arcuate nucleus, Melanocortin receptors, Neuropeptide Y, Melanocyte-stimulating hormone, Feeding behavior
1.
Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG: Central nervous system control of food intake. Nature 2000;404:661–671.
2.
Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD: Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997;385:165–168.
3.
Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A: Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998;19:155–157.
4.
Yaswen Y, Diehl N, Brennan MB, Hochgeschwender U: Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 1999;5:1066–1070.
5.
Stanley BG, Leibowitz SF: Neuropeptide Y stimulation of feeding and drinking by injection into the paraventricular nucleus. Life Sci 1984;35:2635–2642.
6.
Clark JT, Kalra PS, Kalra SP: Neuropeptide Y stimulates feeding but inhibits sexual behavior in rats. Endocrinology 1985;117:2435–2442.
7.
Cummings DE, Schwartz MW: Melanocortins and body weight: a tale of two receptors. Nat Genet 2000;26:8–9.
8.
Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield AL, Burn P, Lee F: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997;88:131–141.
9.
Chen AS, Marsh DJ, Trumbauer ME, Frazier EG, Guan XM, Yu H, Rosenblum CI, Vongs A, Feng Y, Cao L, Metzger JM, Strack AM, Camacho RE, Mellin TN, Nunes CN, Min W, Fisher J, Gopal-Truter S, MacIntyre DE, Chen HY, Van der Ploeg LHT: Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000;26:97–102.
10.
Stanley BG, Kyrkouli SE, Lampert S, Leibowitz SF: Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986;7:1189–1192.
11.
Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B: Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993;133:1753–1758.
12.
Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale J, Hoffmann J, Hsiung HM, Kriauciunas A, MacKellar W, Rosteck PR, Schoner B, Smith D, Tinsley FC, Zhang XY, Heiman M: The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995;377:530–532.
13.
Erickson JC, Hollopeter G, Palmiter RD: Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996;274:1704–1707.
14.
Hahn TM, Breininger JF, Baskin DG, Schwartz MW: Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nature 1998;1:271–272.
15.
Lu D, Willard D, Patel IR, Kadwell S, Overton L, Kost T, Luther M, Chen W, Woychik RP, Wilkison WO, Cone RD: Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 1994;371:799–802.
16.
Ollmann MM, Wilson BD, Yang YK, Kerns JA, Chen Y, Gantz I, Barsh GS: Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997;278:135–138.
17.
Dhillo WS, Small CJ, Stanley SA, Jethwa PH, Seal LJ, Murphy KG, Ghatei MA, Bloom SR: Hypothalamic interactions between neuropeptide Y, agouti-related protein, cocaine- and amphetamine-regulated transcript and α-melanocyte-stimulating hormone in vitro in male rats. J Neuroendocrinol 2002;14:725–730.
18.
Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. New York, Academic Press, 1982.
19.
Jégou S, Boutelet I, Vaudry H: Melanocortin-3 receptor mRNA expression in pro-opiomelanocortin neurones of the rat arcuate nucleus. J Neuroendocrinol 2000;12:501–505.
20.
Tong Y, Zhao HF, Labrie F, Pelletier G: Regulation of proopiomelanocortin messenger ribonucleic acid content by sex steroids in the arcuate nucleus of the female rat brain. Neurosci Lett 1990;112:104–108.
21.
Bouret S, Prevot V, Croix D, Howard A, Habert-Ortoli E, Jégou S, Vaudry H, Beauvillain JC, Mitchell V: Expression of GalR1 and GalR2 galanin receptor messenger ribonucleic acid in proopiomelanocortin neurons of the rat arcuate nucleus: effect of testosterone. Endocrinology 2000;141:1780–1794.
22.
Allen YS, Adrian TE, Allen JM, Tatemoto K, Crow TJ, Bloom SR, Polak JM: Neuropeptide Y distribution in the rat brain. Science 1983;221:877–879.
23.
Chronwall BM: Anatomy and physiology of the neuroendocrine arcuate nucleus. Peptides 1985;6:1–11.
24.
Umegaki K, Shiosaka S, Kawai Y, Shinoda K, Yagura A, Shibasaki T, Ling N, Tohyama M: The distribution of α-melanocyte-stimulating hormone in the central nervous system of the rat: an immunohistochemical study. I. Forebrain and upper brain stem. Cell Mol Biol 1983;29:377–386.
25.
Jégou S, Delbende C, Tranchand-Bunel D, Leroux P, Vaudry H: α-Melanocyte-stimulating hormone release from perifused rat hypothalamic slices. Brain Res 1987;413:259–266.
26.
Roselli-Rehfuss L, Mountjoy KG, Robbins LS, Mortrud MT, Low MJ, Tatro JB, Entwistle ML, Simerly RB, Cone RD: Identification of a receptor for γ-melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci USA 1993;90:8856–8860.
27.
Mountjoy KG, Mortrud MT, Low MJ, Simerly RB, Cone RD: Localization of the melanocortin-4 receptor in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 1994;8:1298–1308.
28.
Csiffary A, Gorcs TJ, Palkovits M: Neuropeptide Y innervation of ACTH-immunoreactive neurons in the arcuate nucleus of rats: a correlated light and electron microscopic double immunolabeling study. Brain Res 1990;506:215–222.
29.
Broberger C, Landry M, Wong H, Walsh JN, Hökfelt T: Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology 1997;66:393–408.
30.
Roseberry AG, Liu H, Jackson AC, Cai X, Friedman JM: Neuropeptide Y-mediated inhibition of proopiomelanocortin neurons in the arcuate nucleus shows enhanced desensitization in ob/ob mice. Neuron 2004;41:711–722.
31.
Blasquez C, Jégou S, Tranchand Bunel D, Fournier A, Vaudry H: Neuropeptide Y inhibits α-MSH release from rat hypothalamic slices through a pertussis toxin-sensitive G protein. Brain Res 1992;596:163–168.
32.
Blasquez C, Jégou S, Friard O, Tonon MC, Fournier A, Vaudry H: Effect of centrally administered neuropeptide Y on hypothalamic and hypophyseal proopiomelanocortin-derived peptides in the rat. Neuroscience 1995;68:221–227.
33.
Garcia de Yebenes E, Li S, Fournier A, St-Pierre S, Pelletier G: Regulation of proopiomelanocortin gene expression by neuropeptide Y in the rat arcuate nucleus. Brain Res 1995;674:112–116.
34.
Horvath TL, Bechmann I, Naftolin F, Kalra SP, Leranth C: Heterogeneity in the neuropeptide Y-containing neurons of the rat arcuate nucleus: GABAergic and non-GABAergic subpopulations. Brain Res 1997;756:283–286.
35.
Delbende C, Jégou S, Tranchand-Bunel D, Blasquez C, Vaudry H: Gamma-aminobutyric acid inhibits the release of α-melanocyte-stimulating hormone from rat hypothalamic slices. Brain Res 1989;497:86–93.
36.
Jégou S, Tong Y, Blasquez C, Pelletier G, Vaudry H: Activation of the GABAA-benzodiazepine receptor complex inhibits proopiomelanocortin gene expression in the rat arcuate nucleus. Mol Cell Neurosci 1991;2:4404–4445.
37.
Cowley MA, Smart JL, Rubinstein M, Cerdan MG, Diano S, Horvath TL, Cone RD, Low MJ: Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus. Nature 2001;411:480–484.
38.
Cowley MA, Pronchuk N, Fan W, Dinulescu DM, Colmers WF, Cone RD: Integration of NPY, AGRP, and melanocortin signals in the hypothalamic paraventricular nucleus: evidence of a cellular basis for the adipostat. Neuron 1999;24:155–163.
39.
Bagnol D, Lu XY, Kaelin CB, Day HE, Ollmann M, Gantz I, Akil H, Barsh GS, Watson SJ: Anatomy of an endogenous antagonist: relationship between agouti-related protein and proopiomelanocortin in brain. J Neurosci 1999;19:RC26.
40.
Chen YY, Pelletier G: Demonstration of contacts between proopiomelanocortin neurons in the rat hypothalamus. Neurosci Lett 1983;43:271–276.
© 2005 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.